Simon J. Dovedi
YOU?
Author Swipe
View article: Characterisation of human in vitro tumour-associated macrophage models to define translational relevance
Characterisation of human in vitro tumour-associated macrophage models to define translational relevance Open
Tumour-associated macrophages (TAMs) are key components of the tumour microenvironment with a demonstrated ability to modulate anti-tumour T-cell responses and immunotherapy outcomes. With increasing realisation that the M1/M2 paradigm doe…
View article: Supplementary Tables from Small Gene Networks Delineate Immune Cell States and Characterize Immunotherapy Response in Melanoma
Supplementary Tables from Small Gene Networks Delineate Immune Cell States and Characterize Immunotherapy Response in Melanoma Open
Supplementary Tables S1 and S2
View article: Supplementary Figures from Small Gene Networks Delineate Immune Cell States and Characterize Immunotherapy Response in Melanoma
Supplementary Figures from Small Gene Networks Delineate Immune Cell States and Characterize Immunotherapy Response in Melanoma Open
Supplementary Figures S1 and S2
View article: 852 AZD6750: design and efficacy of a CD8-guided IL-2 that enhances CD8 <sup>+</sup> T cell function
852 AZD6750: design and efficacy of a CD8-guided IL-2 that enhances CD8 <sup>+</sup> T cell function Open
View article: Figure S7 from <i>In Vivo</i> Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade
Figure S7 from <i>In Vivo</i> Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade Open
Supplementary figure 7
View article: Figure S5 from <i>In Vivo</i> Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade
Figure S5 from <i>In Vivo</i> Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade Open
Supplementary figure 5
View article: Figure S3 from <i>In Vivo</i> Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade
Figure S3 from <i>In Vivo</i> Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade Open
Supplementary figure 3
View article: Figure S2 from <i>In Vivo</i> Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade
Figure S2 from <i>In Vivo</i> Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade Open
Supplementary figure 2
View article: Figure S10 from <i>In Vivo</i> Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade
Figure S10 from <i>In Vivo</i> Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade Open
Supplementary figure 10
View article: Data from <i>In Vivo</i> Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade
Data from <i>In Vivo</i> Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade Open
Tumor-associated macrophages (TAM) are a universal feature of cancers but variably influence outcomes and treatment responses. In this study, we used a photoconvertible mouse to distinguish newly entering, monocyte-derived TAMs (mdTAM) tha…
View article: Figure S8 from <i>In Vivo</i> Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade
Figure S8 from <i>In Vivo</i> Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade Open
Supplementary figure 8
View article: Supplementary table 1 from <i>In Vivo</i> Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade
Supplementary table 1 from <i>In Vivo</i> Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade Open
Antibodies and reagents
View article: Figure S1 from <i>In Vivo</i> Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade
Figure S1 from <i>In Vivo</i> Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade Open
Supplementary figure 1
View article: Figure S6 from <i>In Vivo</i> Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade
Figure S6 from <i>In Vivo</i> Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade Open
Supplementary figure 6
View article: Figure S4 from <i>In Vivo</i> Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade
Figure S4 from <i>In Vivo</i> Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade Open
Supplementary figure 4
View article: Figure S9 from <i>In Vivo</i> Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade
Figure S9 from <i>In Vivo</i> Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade Open
Supplementary figure 9
View article: An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release
An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release Open
Background AZD5863 is a bispecific T cell engager (TCE) with high affinity to CLDN18.2 and low affinity to cluster of differentiation 3 (CD3), designed to decrease its peripheral cytokine release potential, improve the therapeutic index, a…
View article: Innovative strategies for T cell engagers for cancer immunotherapy
Innovative strategies for T cell engagers for cancer immunotherapy Open
T cell engagers (TCEs) are a promising class of cancer immunotherapy that re-direct T cells to kill tumor cells. However, their clinical application is limited by several challenges, including cytokine release syndrome (CRS), on-target off…
View article: A comprehensive welfare scoring system for graft versus host disease clinical assessment in humanised mouse models used for pharmaceutical research
A comprehensive welfare scoring system for graft versus host disease clinical assessment in humanised mouse models used for pharmaceutical research Open
Immuno-oncology drug discovery increasingly relies on humanised mouse models of cancer due to limitations of murine surrogate tools and differences between mouse and human immune systems. Graft-versus-Host Disease (GvHD) is a significant c…
View article: <i>In Vivo</i> Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade
<i>In Vivo</i> Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade Open
Tumor-associated macrophages (TAM) are a universal feature of cancers but variably influence outcomes and treatment responses. In this study, we used a photoconvertible mouse to distinguish newly entering, monocyte-derived TAMs (mdTAM) tha…
View article: LILRB2 blockade facilitates macrophage repolarization and enhances T cell-mediated antitumor immunity
LILRB2 blockade facilitates macrophage repolarization and enhances T cell-mediated antitumor immunity Open
Background Immune checkpoint inhibitors have revolutionized the treatment of solid tumors, enhancing clinical outcomes by releasing T cells from inhibitory effects of receptors like programmed cell death protein 1 (PD-1). Despite these adv…
View article: Utility of ctDNA assessment after six weeks of immunotherapy to predict radiological response in advanced oesophageal cancer
Utility of ctDNA assessment after six weeks of immunotherapy to predict radiological response in advanced oesophageal cancer Open
The prospective, single-arm CALIBRATION trial (NCT03653052) assessed liquid biopsies for early response concordance compared with CT scan assessment in patients with advanced oesophageal cancer given durvalumab (PD-L1 inhibitor) after at l…
View article: 1058 Development of AZD9793 for GPC3<sup>+</sup> solid tumor treatment: a next generation CD8-guided T cell engager with superior therapeutic index versus conventional formats
1058 Development of AZD9793 for GPC3<sup>+</sup> solid tumor treatment: a next generation CD8-guided T cell engager with superior therapeutic index versus conventional formats Open
View article: 1093 Development of TITAN: a new CD8-guided T cell engager platform for hematological and solid tumor applications
1093 Development of TITAN: a new CD8-guided T cell engager platform for hematological and solid tumor applications Open
View article: Supplementary Table S2 from Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control
Supplementary Table S2 from Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control Open
Growth Rate
View article: Data from Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control
Data from Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control Open
Purpose:Combining radiotherapy (RT) with DNA damage response inhibitors may lead to increased tumor cell death through radiosensitization. DNA-dependent protein kinase (DNA-PK) plays an important role in DNA double-strand break repair via …
View article: Supplementary Figure 1-9 from Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control
Supplementary Figure 1-9 from Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control Open
Supplementary Figure 1-9
View article: Supplementary Figure Legends from Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control
Supplementary Figure Legends from Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control Open
Supplementary Figure Legends
View article: Supplementary Table S1 from Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control
Supplementary Table S1 from Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control Open
Plating Efficiency
View article: 76P Immune engager compounds screening using CRC patient-derived organoids
76P Immune engager compounds screening using CRC patient-derived organoids Open